Log In
Print this Print this

CaspaCIDe T cells (BPX-501)

  Manage Alerts
Collapse Summary General Information
Company Bellicum Pharmaceuticals Inc.
DescriptionAdjunct T cell therapy consisting of genetically modified donor T cells containing the CaspaCIDe safety switch
Molecular Target
Mechanism of Action 
Therapeutic ModalityActive immunotherapy

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today